Because BRM and BRG1 are frequently mutated in cancer3, we investigated if cancer cell lines with SWI/SNF mutations showed low GTF2H1 protein levels, as these cells would then likely be more susceptible to DNA damaging chemotherapeutic drugs. This evidence concerns the gene GTF2H1 and cancer.